Mriglobal
Mriglobal, doing business as Midwest Research Institute, is a 501(c)(3) not-for-profit research organization that provides scientific research, testing, training, and product development services to federal and commercial clients. The company specializes in areas such as medical countermeasure development, biosafety testing, threat detection technologies, and specialized training programs. Mriglobal conducts over $110 million in annual research for federal agencies including the Department of Health and Human Services, Department of Defense, and Department of Homeland Security. Through federal contract and grant awards, Mriglobal delivers a wide range of capabilities including analytical testing, biorepository management, pharmaceutical manufacturing, and infectious disease research.
Mriglobal has received numerous prime federal contract awards for diverse projects across multiple agencies. For the Department of Health and Human Services, Mriglobal has provided services such as drug toxicity testing, stability studies of investigational drugs, and maintenance of chemopreventive agent repositories for the National Institutes of Health. The company has also supported the Centers for Disease Control and Prevention with bacterial panel production and laboratory response network services. For the Department of Defense, Mriglobal has conducted research on nerve agent detection in military working dogs and provided biocontainment systems. The company has also supported the Department of Homeland Security with test and evaluation services for chemical countermeasures. Many of Mriglobal's contract awards involve specialized scientific equipment, biocontainment units, and laboratory services. The company frequently serves as both a prime contractor and subcontractor, partnering with universities, other research institutes, and small businesses to deliver comprehensive research and development services.
In terms of federal grant awards, Mriglobal has received funding to enhance its biorepository and life sciences capabilities. A $5 million grant from the Department of Health and Human Services is supporting the expansion of Mriglobal's biorepository facility in North Kansas City, Missouri, to advance the management of biologics and biological samples for clinical studies. Another grant is funding the expansion of life sciences capabilities at Mriglobal's headquarters to support research for multiple NIH organizations. As a subrecipient, Mriglobal has contributed to university-led research projects on topics such as dexamethasone therapy for ocular injuries from vesicating agents, development of antidotes for toxic gases, and sequencing of tick-borne viral disease agents. These grant-funded projects leverage Mriglobal's expertise in areas like analytical testing, animal studies, and specialized laboratory services.
Mriglobal holds several significant federal contract IDVs that enable agencies to rapidly procure its services. A $146.3 million IDV from the National Institute of Allergy and Infectious Diseases supports pre-clinical evaluation of infectious disease countermeasures. Another $49.7 million IDV from the National Center for Advancing Translational Sciences covers chemistry, manufacturing, and controls services for drug substance development. Mriglobal also holds a $100 million IDV from the Office of the Assistant Secretary for Preparedness and Response for biological animal model and medical countermeasure development. The company's IDVs span a range of capabilities including safety evaluation studies, diagnostic pre-clinical services, and rapid response research support. These vehicles allow agencies like NIH, CDC, and BARDA to issue task orders for Mriglobal's specialized scientific and technical services on an as-needed basis to support critical public health and national security programs.
HKQHNFKNKL15 541715
Not listed 425 Dr Martin Luther King Jr Blvd, Kansas City, MO 64110, USA
7/24/01 1/3/26 Murty Pharmaceuticals, Inc.
Murty Pharmaceuticals, Inc. is a pharmaceutical company focused on research activities and commercial manufacturing in partnership with government and private companies. They provide drug product development, scale up, stability testing, and production services to support substance abuse and addiction treatment research programs.
Through prime federal contract awards, Murty Pharmaceuticals performs stability studies, manufactures morphine sulfate pellets, and produces methamphetamine hydrochloride in support of the National Institute on Drug Abuse's efforts to develop medications for substance use disorders. Awards have funded the company to conduct cGMP manufacturing, quality control testing, and stability assessments in compliance with FDA regulations. All work is performed at Murty's Lexington, Kentucky facility.
Murty Pharmaceuticals holds an indefinite delivery contract from the National Institute on Drug Abuse for pharmaceutical development and manufacturing with a potential value of $7 million. Task orders issued against this contract vehicle encompass formulation development, clinical trial materials production, and associated analytical testing. Additionally, the company was awarded a spot on a $45 million IDIQ contract from NIH for drug formulation and manufacturing in support of various agency research programs.
DNJBTJ3XBQM6 325412
Not listed 518 Codell Dr, Lexington, KY 40509, USA
9/12/02 2/11/26 Societal Cdmo San Diego, LLC
Societal Cdmo San Diego, LLC, doing business as Irisys Inc., is a contract development and manufacturing organization (CDMO) specializing in pharmaceutical product development, manufacturing, and testing services for federal government agencies. Registered in SAM.gov since January 2015, the company is a self-certified small disadvantaged business structured as a for-profit limited liability company and a subsidiary of Recro Pharma, Inc. The organization provides critical pharmaceutical services across various therapeutic areas, with a primary focus on developing and manufacturing investigational drugs for clinical trials and research purposes.
The company has consistently provided pharmaceutical development services to multiple federal agencies, particularly within the National Institutes of Health (NIH) ecosystem. Its contract awards primarily involve developing and manufacturing specialized drug products, including capsules, injectable solutions, and nasal sprays for clinical research. Societal Cdmo has worked extensively with agencies such as the National Cancer Institute, National Center for Advancing Translational Sciences, National Institute on Drug Abuse, and the Department of Veterans Affairs. The majority of its contracts are firm fixed-price delivery orders under multiple award indefinite delivery/indefinite quantity (IDIQ) contract vehicles, focusing on drug product development across oncology, neurology, addiction, and rare disease research. Most contracts are not set aside for specific business categories, demonstrating the company's competitive capabilities in pharmaceutical manufacturing and development.
Societal Cdmo holds two primary federal contract Indefinite Delivery Vehicles (IDVs), both with civilian agencies. The first is a single-award IDV with the Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 4, valued at $2,010,645 and running through April 2026, focused on pharmaceutical manufacturing of imiquimod products. The second IDV, also a single-award contract, was established with the same VA network in December 2021, valued at $1,573,950, specifically for imiquimod research study support. These IDVs enable the company to provide specialized pharmaceutical manufacturing services, including developing active pharmaceutical ingredients, creating placebo formulations, and supporting clinical research through precise, FDA-compliant manufacturing processes.
YRPTVKHDL7Z5 325412
Not listed 6828 Nancy Ridge Dr #100, San Diego, CA 92121, USA
1/27/15 3/18/25 Eminent Services Corp
Eminent Services Corp is a leading provider of pharmaceutical, biological, and infotech services to the pharmaceutical and biotechnology industry. Through prime federal contracts, Eminent Services Corp has provided clinical trial and data management services to the National Institutes of Health's National Institute of Allergy and Infectious Diseases. This has included a $15 million definitive contract to support the Immune Mediated Diseases Clinical Products Center through March 2026. As a prime contractor under an NIH indefinite delivery contract vehicle, Eminent Services Corp provides drug formulation and manufacturing services with a potential value of $45 million through September 2024.
As a subcontractor on federal grants, Eminent Services Corp has provided data coordination services in support of the University of South Florida and the Type 1 Diabetes TrialNet program. This work has involved serving as the data coordinating center across multiple TrialNet grants focused on type 1 diabetes research and clinical trials.
Eminent Services Corp holds an indefinite delivery contract from the National Institutes of Health Office of Logistics and Acquisition Operations for drug formulation and manufacturing services. This multiple award contract vehicle allows Eminent Services Corp to compete for task orders through September 2024, with a total potential value of $45 million.
C4PUY1BKHP59 541715
Not listed 7495 New Technology Way, Frederick, MD 21703, USA
9/28/04 2/13/26 Alchem Laboratories Corporation
Alchem Laboratories Corporation, doing business as Alchem Laboratories Corp, is a custom research organization that performs specialized services including custom organic synthesis, current Good Manufacturing Practice (cGMP) manufacturing, and analytical services. According to its website, Alchem Laboratories is engaged in pharmaceutical manufacturing. The company is registered as a corporate, for-profit manufacturer based in Florida.
Through prime federal contracts, Alchem Laboratories has primarily provided synthesis and analytical testing services for the National Cancer Institute and National Institute of Allergy and Infectious Diseases. Major contracts include a $2.9 million cost-plus-fixed-fee delivery order to synthesize non-GMP small molecule samples for the National Cancer Institute through 2027, and a $3.3 million order to similarly synthesize up to ten sample compounds per year for the Institute's Program 66C through 2026. The company has also received task orders totaling over $17 million under the Preclinical Services for HIV Therapeutics IDIQ to support therapeutic development for HIV/AIDS, providing services such as quality assurance planning, reagent programs, and therapeutic agent synthesis. No small business set-asides were designated for these prime contract awards to Alchem Laboratories.
Through prime federal grants, Alchem Laboratories has been awarded a $474,451 project grant by the Defense Threat Reduction Agency from 2023 to 2027 under the Scientific Research - Combating Weapons of Mass Destruction program. The grant will fund research and development of small molecule inhibitors targeting the Venezuelan equine encephalitis virus, aimed at developing potential medical countermeasures against this biological threat agent.
Alchem Laboratories holds multiple federal indefinite delivery vehicle (IDV) contracts that specify the types of preclinical and manufacturing services the company can provide across task orders. This includes a $12 million National Cancer Institute IDV through 2028 for analysis and synthesis of GMP and non-GMP bulk drugs and pharmaceutical formulations to advance the Institute's cancer research. Alchem is also one of multiple awardees on the $107 million Preclinical Services for HIV Therapeutics IDV awarded by the National Institute of Allergy and Infectious Diseases, through which it will provide services across seven task areas including in vitro testing, small molecule synthesis, animal studies, formulation development, and more. The company additionally has roles on IDVs held by other NIH offices focused on drug formulation and manufacturing support, as well as medicinal chemistry lead optimization services awarded through the National Center for Advancing Translational Sciences.
LD2KY6H7KMQ5 325412
Not listed 13305 Rachael Blvd, Alachua, FL 32615, USA
4/28/03 10/16/25